Publication: 168

A Phase II Study Of Estramustine, Docetaxel, And Bevacizumab In Men With Castrate Resistant Prostate Cancer: Results Of Cancer And Leukemia Group B (CALGB) 90006
      QxMD      Google Scholar   
Citation:
Cancer vol 117 (3) 526-533
Year:
2011
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA032291, CA33601, U10 CA077658, CA77406, CA32291, CA41287, U10 CA035279, U10 CA031946, U10 CA033601, U10 CA045389, CA45389, CA35279, U10 CA045418, U10 CA077440, CA16450, CA77440, U10 CA041287, U10 CA047559, CA47559, CA45418, U10 CA031946-18, CA77658, CA60318, CA77298, CA31946  
Corr. Author:
 
Authors:
                 
Networks:
 
Study
CALGB-90006
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Docetaxel, Bevacizumab, castrate resistant prostate cancer